- Page 3: UBiv»rstt5ts-Krauk8Biiaas Eppendor
- Page 6 and 7: Publication of these proceedings is
- Page 8 and 9: B. Relapse JE Sanders, RHill, F App
- Page 12 and 13: JP Eder and BA Teicher New Agents i
- Page 14 and 15: AMCarella, P Codier, A Congiu, E Ga
- Page 16 and 17: G Rosti, M Leoni, L Atbertazd, R Sa
- Page 18 and 19: B Bostrom Can Maximal Dose Chemothe
- Page 21: ACKNOWLEDGEMENTS The organizers tha
- Page 24 and 25: 4 Session 1: Acute Myelogenous Leuk
- Page 26 and 27: 6 Session 1: Acute Myelogenous Leuk
- Page 29 and 30: 9 ABMT vs. Chemotherapy in Adults:
- Page 31: 11 ABMT vs. Chemotherapy in Adults:
- Page 34 and 35: 14 Session 1: Acute Myelogenous Leu
- Page 36 and 37: 16 Session 1: Acute Myelogenous Leu
- Page 38 and 39: 18 Session 1: Acute Myelogenous Leu
- Page 40 and 41: 20 Session 1: Acute Myelogenous Leu
- Page 43 and 44: 23 Role of Marrow Purging AUTOLOGOU
- Page 45 and 46: Role of Marrow Purging 25 the leuke
- Page 47 and 48: 27 Role of Marrow Purging The distr
- Page 49 and 50: Role of Marrow Purging 29 REFERENCE
- Page 51 and 52: 31 Role of Marrow Purging TABLE 2 A
- Page 53 and 54: 33 Role of Marrow Purging FIGURE 3
- Page 55 and 56: 35 Role of Marrow Purging FIGURE 7
- Page 57 and 58: 37 ABMT: An Eastern Cooperative Onc
- Page 59 and 60: 39 ABMT: An Eastern Cooperative Onc
- Page 61:
41 ABMT: An Eastern Cooperative Onc
- Page 64 and 65:
44 Session 1: Acute Myelogenous Leu
- Page 66 and 67:
46 Session 1: Acute Myelogenous Leu
- Page 68 and 69:
48 Session 1: Acute Myelogenous Leu
- Page 70 and 71:
50 Session 1: Acute Myelogenous Leu
- Page 72 and 73:
52 Session 1: Acute Myelogenous Leu
- Page 74 and 75:
54 Session 1: Acute Myelogenous Leu
- Page 76 and 77:
56 Session 1: Acute Myelogenous Leu
- Page 78 and 79:
58 Session 1: Acute Myelogenous Leu
- Page 80 and 81:
60 Session 1: Acute Myelogenous Leu
- Page 82 and 83:
62 Session 1: Acute Myelogenous Leu
- Page 84 and 85:
64 Session 1: Acute Myelogenous Leu
- Page 86 and 87:
66 Session 1: Acute Myelogenous Leu
- Page 88 and 89:
68 Session 1: Acute Myelogenous Leu
- Page 90 and 91:
70 Session 1: Acute Myelogenous Leu
- Page 92 and 93:
72 Session 1: Acute Myelogenous Leu
- Page 94 and 95:
74 Session 1: Acute Myelogenous Leu
- Page 97 and 98:
77 BAVC Followed by Unpurged Marrow
- Page 99 and 100:
79 BAVCFollowedby Unpurged Marrow I
- Page 101 and 102:
81 ABMT with Unpurged Marrow AUTOLO
- Page 103 and 104:
ABMT with Unpurged Marrow 83 Kaplan
- Page 105 and 106:
85 ABMT with Unpurged Marrow 4. Gol
- Page 107 and 108:
87 ABMT with Unpurged Marrow TABLE
- Page 109:
89 ABMT with Unpurged Marrow FIGURE
- Page 112 and 113:
92 Session 1: Acute Myelogenous Leu
- Page 114 and 115:
94 Session 1: Acute Myelogenous Leu
- Page 116 and 117:
96 Session 1: Acute Myelogenous Leu
- Page 118 and 119:
98 Session 1: Acute Myelogenous Leu
- Page 120 and 121:
100 Session 1: Acute Myelogenous Le
- Page 122 and 123:
102 Session 1: Acute Myelogenous Le
- Page 125 and 126:
105 ABMT with 4-HC Purged Marrow AU
- Page 127 and 128:
107 ABMT with 4-HC Purged Marrow RE
- Page 129 and 130:
109 ABMT with 4-HC Purged Marrow de
- Page 131 and 132:
ABMT wüh 4-HC Purged Marrow TABLE
- Page 133 and 134:
113 MonoclonalAntibody-PurgedABMT N
- Page 135 and 136:
115 Monoclonal Antibody-PurgedABMT
- Page 137 and 138:
117 MonoclonalAntibody-PurgedABMT (
- Page 139 and 140:
119 MonoclonalAntibody-PurgedABMT R
- Page 141 and 142:
121 MonoclonalAntïbody-PurgedABMT
- Page 143 and 144:
123 Prognostic Factors for Hematolo
- Page 145 and 146:
125 Prognostic Factors for Hematolo
- Page 147 and 148:
127 Prognostic Factors for Hematolo
- Page 149 and 150:
129 Prognostic Factors for Hematolo
- Page 151 and 152:
131 Prognostic Factors for Hematolo
- Page 153 and 154:
133 Prognostic Factors for Hematolo
- Page 155 and 156:
135 Cell Proliferation Studies with
- Page 157 and 158:
137 Cell Proliferation Studies with
- Page 159 and 160:
139 Cell Proliferation Studies with
- Page 161 and 162:
Cell Proliferation Studies with AST
- Page 163 and 164:
143 Cell Proliferation Studies with
- Page 165 and 166:
145 Detection of Minimal Residual D
- Page 167 and 168:
147 Detection of Minimal Residual D
- Page 169:
149 Detection of Minimal Residual D
- Page 172 and 173:
152 Session 2: Acute Lymphocytic Le
- Page 174 and 175:
154 Session 2: Acute Lymphocytic Le
- Page 176 and 177:
156 Session 2: Acute Lymphocytic Le
- Page 178 and 179:
158 Session 2: Acute Lymphocytic Le
- Page 180 and 181:
160 Session 2: Acute Lymphocytic Le
- Page 182 and 183:
162 Session 2: Acute Lymphocytic Le
- Page 184 and 185:
164 Session 2: Acute Lymphocytic Le
- Page 187 and 188:
167 ABMT: Report from Dana Farber C
- Page 189 and 190:
169 ABMT: Report from Dana Farber C
- Page 191 and 192:
171 ABMT: Report from Dana Farber C
- Page 193 and 194:
173 ABMT: Report from Dana Farber C
- Page 195 and 196:
175 ABMT: Report from Dana Farber C
- Page 197 and 198:
177 Bone Marrow Purging BONE MARROW
- Page 199 and 200:
179 Bone Marrow Purging intermediat
- Page 201 and 202:
181 Bone Marrow Purging Clinical Ou
- Page 203 and 204:
183 Bone Marrow Purging 12. Ramsay
- Page 205 and 206:
185 Bone Marrow Purging TABLE 4 Sum
- Page 207:
187 Bone Marrow Purging FIGURE 3 Di
- Page 210 and 211:
190 Session 2: Acute Lymphocytic Le
- Page 212 and 213:
192 Session 2: Acute Lymphocytic Le
- Page 214 and 215:
194 Session 2: Acute Lymphocytic Le
- Page 216 and 217:
196 Session 2: Acute Lymphocytic Le
- Page 218 and 219:
198 Session 2: Acute Lymphocytic Le
- Page 220 and 221:
200 Session 2: Acute Lymphocytic Le
- Page 222 and 223:
202 Session 2: Acute Lymphocytic le
- Page 225 and 226:
205 Chemotherapy Regimens and BMT I
- Page 227 and 228:
207 Chemotherapy Regimens and BMT F
- Page 229 and 230:
209 Chemotherapy Regimens and BMT F
- Page 231 and 232:
211 Detection of Minimal Residual L
- Page 233 and 234:
213 Detection of Minimal Residual L
- Page 235 and 236:
215 Detection of Minimal Residual L
- Page 237:
217 Detection of Minimal Residual L
- Page 240 and 241:
220 Session 3: Chronic Myelogenous
- Page 242 and 243:
222 Session 3: Chronic Myelogenous
- Page 244 and 245:
224 Session 3: Chronic Myelogenous
- Page 246 and 247:
226 Session 3: Chronic Myelogenous
- Page 248 and 249:
228 Session 3: Chronic Myelogenous
- Page 250 and 251:
230 Session 3: Chronic Myelogenous
- Page 252 and 253:
232 Session 3: Chronic Myelogenous
- Page 254 and 255:
234 Session 3: Chronic Myelogenous
- Page 256 and 257:
236 Session 3: Chronic Myelogenous
- Page 258 and 259:
238 Session 3: Chronic Myelogenous
- Page 260 and 261:
240 Session 3: Chronic Myelogenous
- Page 262 and 263:
242 Session 3: Chronic Myelogenous
- Page 264 and 265:
244 Session 3: Chronic Myelogenous
- Page 266 and 267:
246 Session 3: Chronic Myelogenous
- Page 268 and 269:
248 Session 3: Chronic Myelogenous
- Page 270 and 271:
250 Session 3: Chronic Myelogenous
- Page 272 and 273:
252 Session 3: Chronic Myelogenous
- Page 275 and 276:
255 Approaches to Prevent Relapse A
- Page 277:
257 Approaches to Prevent Relapse F
- Page 280 and 281:
260 Session 4: Supportive Care in g
- Page 282 and 283:
262 Session 4: Supportive Care REFE
- Page 284 and 285:
264 Session 4: Supportive Care TABL
- Page 287 and 288:
267 Gram-Positive Septicemia CHARAC
- Page 289 and 290:
269 Cram-Positive Septicemia treatm
- Page 291 and 292:
271 Gram-Positive Septicemia Guiot
- Page 293 and 294:
273 Ann' Fungal Therapy FLUCONAZOLE
- Page 295 and 296:
275 Anti Fungal Therapy > different
- Page 297 and 298:
277 Ana Fungal Therapy 19. Kroger H
- Page 299:
279 Ana Fungal Therapy TABLE 2 INTE
- Page 302 and 303:
282 Session 4: Supportive Care port
- Page 304 and 305:
284 Session 4: Supportive Care infe
- Page 306 and 307:
286 Session 4: Supportive Care REFE
- Page 309 and 310:
289 COBE Spectra BONE MARROW CONCEN
- Page 311 and 312:
291 COBE Spectra precursor assay (C
- Page 313 and 314:
293 COBE Spectra TABLE 2 DEPLETION
- Page 315:
295 COBE Spectra FIGURE 2 PROCEDURE
- Page 318 and 319:
298 Session 4: Supportive Care The
- Page 320 and 321:
300 Session 4: Supportive Care DISC
- Page 322 and 323:
302 Session 4: Supportive Care 14.
- Page 324 and 325:
304 Session 4: Supportive Care FIGU
- Page 326 and 327:
306 Session 5: Breast Cancer - Meta
- Page 328 and 329:
308 Session S: Breast Cancer - Meta
- Page 330 and 331:
310 Session 5: Breast Cancer - Meta
- Page 333 and 334:
313 High Dose Therapy wäh ABMT HIG
- Page 335 and 336:
315 High Dose Therapy with ABMT Thi
- Page 337 and 338:
317 High Dose Therapy with ABMT for
- Page 339 and 340:
319 High Dose Therapy with ABMT aut
- Page 341:
321 High Dose Therapy with ABMT TAB
- Page 344 and 345:
324 Session 5: Breast Cancer - Meta
- Page 346 and 347:
326 Session 5: Breast Cancer - Meta
- Page 348 and 349:
328 Session 5: Breast Cancer - Meta
- Page 350 and 351:
330 Session 5: Breast Cancer - Meta
- Page 352 and 353:
332 Session 5: Breast Cancer - Meta
- Page 354 and 355:
334 Session 5: Breast Cancer - Meta
- Page 356 and 357:
336 Session 5: Breast Cancer - Meta
- Page 358 and 359:
338 Session S: Breast Cancer - Meta
- Page 360 and 361:
340 Session 5: Breast Cancer - Meta
- Page 363 and 364:
343 High Dose Therapy and ASC Rescu
- Page 365 and 366:
345 High Dose Therapy and ASC Rescu
- Page 367 and 368:
347 High Dose Therapy and ASC Rescu
- Page 369 and 370:
349 High Dose Therapy and ASC Rescu
- Page 371 and 372:
351 High Dose Therapy and ASC Rescu
- Page 373 and 374:
353 High Dose Chemotherapy andBM HI
- Page 375 and 376:
355 High Dose Chemotherapy and BMT
- Page 377 and 378:
357 High Dose Chemotherapy and BMT
- Page 379 and 380:
359 High Dose Cliemotherapy and BMT
- Page 381:
361 High Dose Qiemotherapy and BM T
- Page 384 and 385:
364 Session 5: Breast Cancer - Pre-
- Page 386 and 387:
366 Session 5: Breast Cancer - Pre-
- Page 388 and 389:
368 Session S: Breast Cancer - Pre-
- Page 390 and 391:
370 Session 5: Breast Cancer - Pre-
- Page 393 and 394:
373 New Agents in Chemotherap NEW A
- Page 395 and 396:
375 New Agents in Chemotherapy of a
- Page 397:
377 New Agents in Chemotherap 17. M
- Page 400 and 401:
380 Session 6: Breast Cancer- Pre-M
- Page 402 and 403:
382 Session 6: Breast Cancer- Pre-M
- Page 404 and 405:
384 Session 6: Breast Cancer- Pre-M
- Page 406 and 407:
386 Session 5: Breast Cancer - Pre-
- Page 408 and 409:
388 Session 5: Breast Cancer - Pre-
- Page 410 and 411:
390 Session 5: Breast Cancer - Pre-
- Page 413 and 414:
393 ABMT: Cooperative Pilot Study R
- Page 415 and 416:
395 ABMT: Cooperative Pilot Study R
- Page 417 and 418:
397 ABMT: Cooperative PUot Study Re
- Page 419 and 420:
399 ABMT: Cooperative Pilot Study R
- Page 421 and 422:
401 ÄBMT' Cooperative Pilot Study
- Page 423 and 424:
403 ABMT: Cooperative Pilot Study R
- Page 425 and 426:
405 Factors Affecting ABMT Results
- Page 427 and 428:
407 Factors Affecting ABMT Results
- Page 429 and 430:
409 Factors Affecting ABMT Results
- Page 431 and 432:
411 Parma Pilot Study RELAPSE OF MA
- Page 433 and 434:
413 Parma Pilot Study ABMT in the p
- Page 435 and 436:
415 Parma Pilot Study Netherlands;
- Page 437:
417 Parma Pilot Study FIGURE 1 PARM
- Page 440 and 441:
420 Session 6: Lymphoma - Non-Hodgk
- Page 442 and 443:
422 Session 6: Lymphoma - Non-Hodgk
- Page 444 and 445:
424 Session 6: Lymphoma - Non-Hodgk
- Page 447 and 448:
427 High Dose Etoposide and Melphal
- Page 449 and 450:
429 High Dose Etoposide and Melphal
- Page 451:
431 High Dose Etoposide and Melphal
- Page 454 and 455:
434 Session 6: Lymphoma - Non-Hodgk
- Page 456 and 457:
436 Session 6: Lymphoma • Non-Hod
- Page 458 and 459:
438 Session 6: Lymphoma - Non-Hodgk
- Page 460 and 461:
440 Session 6: Lymphoma - Non-Hodgk
- Page 462 and 463:
442 Session 6: Lymphoma - Non-Hodgk
- Page 464 and 465:
444 Session 6: Lymphoma • Non-Hod
- Page 466 and 467:
446 Session 6: Lymphoma - Non-Hodgk
- Page 468 and 469:
448 Session 6: Lymphoma - Non-Hodgk
- Page 470 and 471:
450 Session 6: Lymphoma - Non-Hodgk
- Page 472 and 473:
452 Session 6: Lymphoma - Non-Hodgk
- Page 474 and 475:
454 Session 6: Lymphoma - Low Grade
- Page 476 and 477:
456 Session 6: Lymphoma - Low Grade
- Page 478 and 479:
458 Session 6: Lymphoma - Low Grade
- Page 480 and 481:
460 Session 6: Lymphoma - Low Grade
- Page 482 and 483:
462 Session 6: Lymphoma - Low Grade
- Page 485 and 486:
465 Ablative Therapy with ABMT ABLA
- Page 487 and 488:
467 Ablative Therapy with ABMT RESU
- Page 489 and 490:
469 Ablative Therapy with ABMT REFE
- Page 491:
471 Ablative Therapy with ABMT TABL
- Page 494 and 495:
474 Session 6: Non-Hodgkin's Lympho
- Page 496 and 497:
476 Session 6: Non-Hodgkin's Lympho
- Page 498 and 499:
478 Session 6: Non-Hodgkin's Lympho
- Page 500 and 501:
480 Session 6: Lymphoma - Non-Hodgk
- Page 502 and 503:
482 Session 6: Lymphoma - Non-Hodgk
- Page 504 and 505:
484 Session 6: Lymphoma - Non-Hodgk
- Page 507 and 508:
487 Studies with Sequential Transpl
- Page 509 and 510:
489 Studies with Sequential Transpl
- Page 511 and 512:
491 Studies with Sequential Transpl
- Page 513 and 514:
493 Studies with Sequential Transpl
- Page 515 and 516:
495 Studies with Sequential Transpl
- Page 517 and 518:
497 Studies with Sequential Transpl
- Page 519:
499 Studies with Sequential Transpl
- Page 522 and 523:
502 Session 6: Lymphoma - Hodgkin's
- Page 524 and 525:
504 Session 6: Lymphoma - Hodgkin's
- Page 526 and 527:
506 Session 6: Lymphoma - Hodgkin's
- Page 528 and 529:
508 Session 6: Lymphoma - Hodgkin's
- Page 530 and 531:
510 Session 6: Lymphoma - Hodgkin's
- Page 532 and 533:
512 Session 6: Lymphoma - Hodgkin's
- Page 534 and 535:
514 Session 6: Lymphoma - Hodgkin's
- Page 536 and 537:
516 Session 6: Lymphoma - Hodgkin's
- Page 538 and 539:
518 Session 6: Lymphoma - Hodgkin*s
- Page 540 and 541:
520 Session 6: Lymphoma - Hodgldn's
- Page 542 and 543:
522 Session 6: Lymphoma - Hodgkin's
- Page 544 and 545:
524 Session 6: Lymphoma - Hodgkin's
- Page 546 and 547:
526 Session 6: Lymphoma - Hodgkin's
- Page 549 and 550:
529 ABMT and Cooperative Group Tria
- Page 551 and 552:
531 ABMT and Cooperative Group Tria
- Page 553 and 554:
533 ABUT and Cooperative Group Tria
- Page 555 and 556:
535 ABMTand Cooperative Group Trial
- Page 557:
537 ABMTandCooperative Group Trials
- Page 560 and 561:
540 Session 6: Lymphoma PATIENTS AN
- Page 562 and 563:
542 Session 6: Lymphoma RESULTS Lym
- Page 564 and 565:
544 Session 6: Lymphoma with TBI; t
- Page 566 and 567:
546 Session 6: Lymphoma TABLE 1 CON
- Page 568 and 569:
548 Session 6: Lymphoma TABLE 5 PAT
- Page 571 and 572:
551 Prospects for the Future AUTOGR
- Page 573 and 574:
553 Prospects for the Future relaps
- Page 575 and 576:
555 Prospects for the Future amelio
- Page 577 and 578:
557 Prospects for the Future which
- Page 579 and 580:
559 Prospects for the Future OVERVI
- Page 581:
561 Prospects for the Future FIGURE
- Page 584 and 585:
564 Session 6: Lymphoma - Myeloma M
- Page 586 and 587:
566 Session 6: Lymphoma - Myeloma R
- Page 588 and 589:
568 Session 6: Lymphoma - Myeloma 9
- Page 590 and 591:
570 Session 6: Lymphoma - Myeloma F
- Page 592 and 593:
572 Session 6: Lymphoma - Myeloma I
- Page 594 and 595:
574 Session 6: Lymphoma - Myeloma w
- Page 596 and 597:
576 Session 6: Lymphoma - Myeloma T
- Page 598 and 599:
578 Session 6: Lymphoma - Myeloma T
- Page 600 and 601:
580 Session 6: Lymphoma - Myeloma F
- Page 602 and 603:
582 Session 6: Lymphoma - Myeloma A
- Page 604 and 605:
584 Session 6: Lymphoma - Myeloma R
- Page 607 and 608:
587 Neuroblastoma in Children OUTCO
- Page 609 and 610:
589 Neuroblastoma in Children the 3
- Page 611 and 612:
591 Neuroblastoma in Children Remis
- Page 613 and 614:
593 Neuroblastoma in Children TABLE
- Page 615 and 616:
595 Neuroblastoma in Children FIGUR
- Page 617:
597 Neuroblastoma in Children FIGUR
- Page 620 and 621:
600 Session 7: Solid Tumors and Eto
- Page 622 and 623:
602 Session 7: Solid Tumors patient
- Page 624 and 625:
604 Session 7: Solid Tumors state a
- Page 626 and 627:
606 Session 7: Solid Tumors TABLE l
- Page 628 and 629:
608 Session 7: Solid Tumors TABLE 2
- Page 630 and 631:
610 Session 7: Solid Tumors TABLE 4
- Page 632 and 633:
612 Session 7: Solid Tumors was ass
- Page 634 and 635:
614 Session 7: Solid Tumors microme
- Page 636 and 637:
616 Session 7: Solid Tumors 13. Dim
- Page 638 and 639:
618 Session 7: Solid Tumors TABLE 2
- Page 640 and 641:
620 Session 7: Solid Tumors Protoco
- Page 642 and 643:
622 Session 7: Solid Tumors at diag
- Page 644 and 645:
624 Session 7: Solid Tumors immunol
- Page 646 and 647:
626 Session 7: Solid Tumors 3. Favr
- Page 648 and 649:
628 Session 7: Solid Tumors TABLE I
- Page 650 and 651:
630 Session 7: Solid Tumors TABLE m
- Page 652 and 653:
632 Session 7: Solid Tumors childre
- Page 654 and 655:
634 Session 7: Solid Tumors 6. Doug
- Page 656 and 657:
636 Session 7: Solid Tumors FIGURE
- Page 658 and 659:
638 Session 7: Solid Tumors BCNU wa
- Page 660 and 661:
640 Session 7: Solid Tumors enhance
- Page 662 and 663:
642 Session 7: Solid Tumors constan
- Page 664 and 665:
644 Session 7: Solid Tumors TABLE 2
- Page 667 and 668:
647 Germ Cell Neoplasms DOSE INTENS
- Page 669 and 670:
649 Germ &tt Neoplasms Indiana Univ
- Page 671 and 672:
651 Germ CeUNeophsms Non-hematologi
- Page 673:
653 Germ Cell Neoplasms Cancer. A S
- Page 676 and 677:
656 Session 7: Solid Tumors Twelve
- Page 678 and 679:
658 Session 7: Solid Tumors 5. Rich
- Page 681 and 682:
661 Dose Intensive Therapy DOSE INT
- Page 683 and 684:
663 Dose Intensive Therapy compared
- Page 685 and 686:
665 Dose Intensive Therapy of thera
- Page 687:
6 6 7 Dose Intensive Therapy TABLE
- Page 690 and 691:
670 Session 7: Solid Tumors drugs c
- Page 692 and 693:
672 Session 7: Solid Tumors cisplat
- Page 694 and 695:
674 Session 7: Solid Tumors TABLE 1
- Page 697 and 698:
677 Conditioning Regimen for BMT BU
- Page 699 and 700:
679 Conditioning Regimen for BMT To
- Page 701 and 702:
681 Conditioning Regimen for BMT TA
- Page 703 and 704:
683 Conditioning Regimen for BMT TA
- Page 705:
685 Conditioning Regimen for BMT FI
- Page 708 and 709:
688 Session 7: Solid Tumors consist
- Page 710 and 711:
690 Session 7: Solid Tumors TABLE 1
- Page 713 and 714:
693 ABMT for Arthritis in Rats REMI
- Page 715 and 716:
695 ABMT for Arthritis in Rats It i
- Page 717:
697 ABMT for Arthritis in Rats FIGU
- Page 720 and 721:
700 Session 8: New Avenues MATERIAL
- Page 722 and 723:
702 Session 8: New Avenues positive
- Page 724 and 725:
704 Session 8: New Avenues Previous
- Page 726 and 727:
706 Session 8: New Avenues FIGURE 1
- Page 728 and 729:
708 Session 8: New Avenues FIGURE 3
- Page 730 and 731:
710 Session 8: New Avenues FIGURE 5
- Page 732 and 733:
712 Session 8: New Avenues to thiou
- Page 734 and 735:
714 Session 8: New Avenues analysis
- Page 736 and 737:
716 Session 8: New Avenues Liver vo
- Page 738 and 739:
718 Session 8: New Avenues TABLE 1
- Page 740 and 741:
720 Session 8: New Avenues FIGURE 2
- Page 742 and 743:
722 Session 8: New Avenues FIGURE 4
- Page 744 and 745:
724 Session 8: New Avenues 1, dose-
- Page 746 and 747:
726 Session 8: New Avenues Bone mar
- Page 748 and 749:
728 Session 8: New Avenues ACKNOWLE
- Page 750 and 751:
730 Session 8: New Avenues TABLE 1
- Page 752 and 753:
732 Session 8: New Avenues FIGURE 3
- Page 754 and 755:
734 Session 8: New Avenues transfer
- Page 756 and 757:
736 Session 8: New Avenues a concen
- Page 758 and 759:
738 Session 8: New Avenues Beta 5'U
- Page 760 and 761:
740 Session 8: New Avenues 5. Stoec
- Page 762 and 763:
742 Session 8: New Avenues FIGURE 2
- Page 764 and 765:
744 Session 8: New Avenues FIGURE 3
- Page 766 and 767:
746 Session 8: New Avenues FIGURE 4
- Page 768 and 769:
748 Session 8: New Avenues FIGURE 5
- Page 771 and 772:
751 Immunocytochemical Detection of
- Page 773 and 774:
753 Immunocytochemical Detection of
- Page 775 and 776:
755 Immunocytochemical Detection of
- Page 777 and 778:
757 Immunocytochemical Detection of
- Page 779 and 780:
759 Immunocytochemical Detection of
- Page 781 and 782:
761 Immunocytochemical Detection of
- Page 783 and 784:
763 Immunotherapy: Post-ABMT Implic
- Page 785 and 786:
765 Immunotherapy: Post-ABMT Implic
- Page 787 and 788:
767 Immunotherapy: Post-ABMT Implic
- Page 789 and 790:
769 Immunotherapy: Post-ABMT Implic
- Page 791 and 792:
771 Immunostimulation Post-ABMT IMM
- Page 793 and 794:
773 Immunostimulation Post-ABMT are
- Page 795 and 796:
775 Immunostimulation Post-ABMT cul
- Page 797 and 798:
Ill Immunostimulation Post-ABMT 4.
- Page 799 and 800:
779 Immunostimulation Post-ABMT FIG
- Page 801 and 802:
781 ImmuMstimuIation Post-ABMT FIGU
- Page 803 and 804:
783 Myelosuppressive Chemotherapy P
- Page 805 and 806:
785 Myelosuppressive Chemotherapy P
- Page 807 and 808:
787 Myelosuppressive Chemotherapy m
- Page 809 and 810:
789 Myelosuppressive Chemotherapy T
- Page 811 and 812:
791 Mobilization Techniques THE ROL
- Page 813 and 814:
793 Mobilization Techniques Cell an
- Page 815 and 816:
795 Mobilization Techniques 8. Bran
- Page 817 and 818:
797 Mobilization Techniques FIGURE
- Page 819:
799 Mobilization Techniques FIGURE
- Page 822 and 823:
802 Session 9: Peripheral Stem Ceil
- Page 824 and 825:
804 Session 9: Peripheral Stem Cell
- Page 826 and 827:
806 Session 9: Peripheral Stern Cel
- Page 828 and 829:
808 Session 9: Peripheral Stem Cell
- Page 830 and 831:
810 Session 9: Peripheral Stem Cell
- Page 832 and 833:
812 Session 9: Peripheral Stem Cell
- Page 834 and 835:
814 Session 9: Peripheral Stem Cell
- Page 836 and 837:
816 Session 9: Peripheral Stem Cell
- Page 838 and 839:
818 Session 9: Peripheral Stem Cell
- Page 840 and 841:
820 Session 9: Peripheral Stem Cell
- Page 843 and 844:
823 Acute Myeloid Leukemia PERIPHER
- Page 845 and 846:
825 Acute Myeloid Leukemia leukemic
- Page 847:
827 Acute Myeloid Leukemia after hi
- Page 850 and 851:
830 Session 9: Peripheral Stem Cell
- Page 852 and 853:
832 Session 9: Peripheral Stem Cell
- Page 854 and 855:
834 Session 9: Peripheral Stem Cell
- Page 857 and 858:
837 Relapsed Lymphomas and Marrow M
- Page 859 and 860:
839 Relapsed Lymphomas and Marrow M
- Page 861 and 862:
841 High Risk Myeloma AUTOLOGOUS BL
- Page 863 and 864:
843 High Risk Myeloma analysis for
- Page 865 and 866:
845 High Risk Myeloma encountered,
- Page 867 and 868:
847 High Risk Myeloma 10. Debecker
- Page 869:
849 High Risk Myeloma TABLE 2 ABSCT
- Page 872 and 873:
852 Session 10: Hematopoietic Growt
- Page 874 and 875:
854 Session 10: Hematopoietic Growt
- Page 876 and 877:
856 Session 10: Hematopoietic Growt
- Page 878 and 879:
858 Session 10: Hematopoietic Growt
- Page 880 and 881:
860 Session 10: Hematopoietic Growt
- Page 882 and 883:
862 Session 10: Hematopoietic Growt
- Page 884 and 885:
864 Session 10: Hematopoietic Growt
- Page 886 and 887:
866 Session 10: Hematopoietic Growt
- Page 888 and 889:
868 Session 10: Hematopoietic Growt
- Page 890 and 891:
870 Session 10: Hematopoietic Growt
- Page 892 and 893:
872 Session 10: Hematopoietic Growt
- Page 894 and 895:
874 Session 10: Hematopoietic Growt
- Page 896 and 897:
876 Session 10: Hematopoietic Growt
- Page 898 and 899:
878 Session 10: Hematopoietic Growt
- Page 901 and 902:
881 Role of Monocytes THE ROLE OF M
- Page 903 and 904:
883 Role of Monocytes cells, always
- Page 905 and 906:
885 Role of Monocytes CONCLUSION Th
- Page 907 and 908:
887 Role of Monocytes TABLE 2 Proge
- Page 909 and 910:
889 Role of Monocytes FIGURE 1 cont
- Page 911 and 912:
891 Role of Monocytes FIGURE 3 Kine
- Page 913 and 914:
893 InterleuIdn-2 Post-ABMT USE OF
- Page 915 and 916:
895 Iníerkukin-2 Posí-ABMT Specif
- Page 917 and 918:
897 Interleukin-2 Post-ABMT years;
- Page 919 and 920:
899 Interieukin-2 Post-ABMT 19. Lau
- Page 921 and 922:
901 Interleukin-2 Post-ABMT TABLE 2
- Page 923 and 924:
903 Interleuldn-2 Post-ABMT FIGURE
- Page 925 and 926:
905 Autotransplants: Present and Fu
- Page 927 and 928:
907 Autotransplants: Present and Fu
- Page 929:
909 Autotransplants: Present and Fu
- Page 932 and 933:
912 Session 11: Concluding Remarks
- Page 935 and 936:
CONTRIBUTORS Tauseef Ahmed, M.D., N
- Page 937 and 938:
Anthony Elias, M.D., Dana Färber C
- Page 939 and 940:
Per Ljungman, M.D., Ph.D., Departme
- Page 941:
Yoichi Takaue, M.D., Department of